Briana Contreras

A Cencora analysis of 32 pre-approval products found more than 60% of payer engagement with PIE resources came more than 90 days after posting.

AMCP leaders say PBM reform, new drug pricing models and AI will shape this week’s Nexus meeting in San Diego.

AI analyzes single-lead ECGs from sleep studies to predict atrial fibrillation, heart failure, and mortality risk, enabling scalable cardiovascular disease screening.

A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.

Intensive systolic blood pressure targets cut CVD risk 15% per 10 mm Hg—similar with or without CKD—while eGFR drops rise, requiring monitoring.

Fewer than 1 in 5 eligible adults get lung cancer screening. Experts told MHE over email that health plans can help by easing cost, coverage and approval barriers.

The pope's lung nodule was found during a routine exam. In the U.S., only 18.7% of adults eligible for lung cancer screening are up to date.

Reimagine Care's CEO says one-off hospital approvals slow CAR-T access and urges buyers to ask vendors to prove outcomes such as avoided ED visits.

Meta-analysis links assisted reproduction tech (ART) to higher risks of major heart defects in pregnancies, urging targeted screening and long-term heart health follow-up.

Reading C-peptide alongside glucose could better predict which autoantibody-positive people will develop type 1 diabetes and detect treatment effects sooner.

Topical steroids remain first-line for chronic hand eczema, but long-term use can thin the skin and leave patients with poorly controlled disease.

Laura Ferris urges risk-based melanoma screening and highlights earlier immunotherapy, selective imaging, vaccine limits and new post–PD-1 options.

Patients with HS should get three to four months on a biologic before a switch, says a dermatologist who sees promise in oral JAK inhibitors.

With three FDA-approved biologics for hidradenitis suppurativa, Jennifer Hsiao, M.D., said patient preference and access often decide which comes first.

Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.

Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.

How LLM decision support reshapes dermatology care, helping non-specialists diagnose while navigating trust gaps, ambiguity, and hallucination risks at Fall Clinical Derm.

Real-world data at the 2026 Fall Clinical Dermatology Conference show dupilumab in children with atopic dermatitis cuts new allergies and asthma risk versus steroids.

Sagimet CEO David Happel shares insights on denifanstat, highlighting strong acne response, tolerability and optimism for a denifanstat U.S. trial.

Sagimet CEO David Happel says oral denifanstat could sharply cut antibiotic use in acne and be used before patients ever need isotretinoin.

Sagimet Biosciences’ denifanstat oral acne pill shows rapid, sustained lesion cuts and higher clear-skin rates in phase 3, offering an antibiotic-sparing option.

Breakthroughs in 2026 dermatology spotlight oral psoriasis drugs nearing biologics, weight-loss combos for PsA, personalized mRNA melanoma vaccines and expanding OTC acne options.

Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.

Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.

Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.

CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.

State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.

Tariffs on patented drugs broaden beyond Big Pharma, and exemptions, MFN deals and origin caps determine rates and potential price pressure.

Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.

Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.